<DOC>
	<DOC>NCT01978587</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis</brief_summary>
	<brief_title>Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>Subjects who have ESRD and have been receiving maintenance hemodialysis for at least 12 weeks prior to the Screening Visit Body weight (postdialysis weight) greater than 45.0 kg and a body mass index between 20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to admission Uncontrolled hypertension at the Screening Visit or Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>End-stage Renal Disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>